|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/506 | (2006.01) |
| C07K 16/2803 | (2013.01) | ||
| A61K 31/635 | (2006.01) | ||
| C07K2317/24 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61K2039/545 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K2039/54 | (2013.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61K 39/3955 | (2013.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61K2039/505 | (2013.01) | ||
| A61K 31/506 | (2013.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 31/635 | (2013.01) |
| (11) | Number of the document | 3897647 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19835803.8 |
| Date of filing the European patent application | 2019-12-18 | |
| (97) | Date of publication of the European application | 2021-10-27 |
| (45) | Date of publication and mention of the grant of the patent | 2023-11-01 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2019/061014 |
| Date | 2019-12-18 |
| (87) | Number | WO 2020/128894 |
| Date | 2020-06-25 |
| (30) | Number | Date | Country code |
| 201862782727 P | 2018-12-20 | US | |
| 201862782730 P | 2018-12-20 | US | |
| 201862782735 P | 2018-12-20 | US |
| (72) |
GUERREIRO, Nelson , CH
HALILOVIC, Ensar , US
JULLION, Astrid , CH
MEILLE, Christophe , CH
WANG, Youzhen , US
FABRE, Claire , CH
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | COMBINATIONS OF A HDM2-P53 INTERACTION INHIBITOR AND A BCL2 INHIBITOR AND THEIR USE FOR TREATING CANCER |
| COMBINATIONS OF A HDM2-P53 INTERACTION INHIBITOR AND A BCL2 INHIBITOR AND THEIR USE FOR TREATING CANCER |